科興首批100萬劑疫苗料本周五抵港 下周可接種
據本地傳媒引述政府消息及科興生物表示,科興首批100萬劑新型冠狀病毒疫苗預計於本周五抵港,倘政府批准緊急使用該疫苗,料下星期可以接種。而復星/BioNTech疫苗「復必泰」預期將於下周抵港。
政府疫苗顧問專家委員會昨天(16日)下午舉行會議,建議政府緊急批准使用科興疫苗。疫苗顧問專家委員會召集人劉澤星表示,科興疫苗對18至60歲人士整體保護率為50.66%,若相隔28日再接種第二劑疫苗,保護率會升至62.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.